<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611621</url>
  </required_header>
  <id_info>
    <org_study_id>17-HMedIdeS-14</org_study_id>
    <nct_id>NCT03611621</nct_id>
  </id_info>
  <brief_title>A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation</brief_title>
  <official_title>A Prospective Observational, Long Term Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hansa Biopharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hansa Biopharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for the current protocol is to collect data from extended follow up in subjects
      that have received a kidney transplant following imlifidase dosing to provide a better
      understanding regarding the long-term outcome for these subjects. Data of parameters such as
      patient and graft survival, comorbidity, treatment of rebound of DSAs and quality of life as
      well as anti-drug antibody levels will be collected.

      This prospective, observational follow up study of subjects who have received imlifidase
      prior to kidney transplantation will provide important data to future prescribers and
      patients of the potential long-term benefits of imlifidase mediated transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of graft survival in subjects who have undergone kidney transplantation after imlifidase administration.</measure>
    <time_frame>5 years after first dose of imlifidase</time_frame>
    <description>The primary endpoint of this study is to determine overall graft survival, defined as time from transplantation to graft loss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of patient survival.</measure>
    <time_frame>5 years after first dose of imlifidase</time_frame>
    <description>Overall patient survival defined as time from transplantation to death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of kidney function (eGFR).</measure>
    <time_frame>5 years after first dose of imlifidase</time_frame>
    <description>Kidney function as evaluated by eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of kidney function (P-creatinine).</measure>
    <time_frame>5 years after first dose of imlifidase</time_frame>
    <description>Kidney function as evaluated by P-creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of kidney function (proteinuria).</measure>
    <time_frame>5 years after first dose of imlifidase</time_frame>
    <description>Kidney function as evaluated by proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of comorbidities and treatments.</measure>
    <time_frame>5 years after first dose of imlifidase</time_frame>
    <description>Record comorbidities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of quality of life (EQ-5D-5L).</measure>
    <time_frame>5 years after first dose of imlifidase</time_frame>
    <description>Health related quality of life (HR-QoL) as evaluated by patient questionnaires EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of quality of life (KDQOL-SF).</measure>
    <time_frame>5 years after first dose of imlifidase</time_frame>
    <description>Health related quality of life (HR-QoL) as evaluated by patient questionnaires KDQOL-SF</description>
  </secondary_outcome>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Kidney Transplant Failure and Rejection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imlifidase</intervention_name>
    <description>This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects that have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.</description>
    <other_name>IdeS, HMED-IdeS</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples (storage time: maximum 2 years after completion of the study report according
      to local regulations)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects that have participated, or are currently participating, in the imlifidase kidney
        transplantation studies; 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS-04 and 15-HMedIdeS-06
        will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent obtained before any study-related procedures

          -  Previous dosing with imlifidase followed by kidney transplantation and participation
             in one of the following clinical studies: 13-HMedIdeS-02, 13-HMedIdeS-03,
             14-HMedIdeS-04 or 15-HMedIdeS-06

        Exclusion Criteria:

          -  Individuals deemed unable to comply with the protocol

          -  Inability by the judgment of the investigator to participate in the study for other
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lena Winstedt, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hansa Biopharma AB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gunilla Eckerwall, PhD</last_name>
    <phone>+46 733420405</phone>
    <email>gunilla.eckerwall@hansamedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Sonesson, PhD</last_name>
    <phone>+46 708548646</phone>
    <email>elisabeth.sonesson@hansamedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Jordan, MD</last_name>
      <phone>310-423-8282</phone>
      <email>Stan.Jordan@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Stanley Jordan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niraj Desai, MD</last_name>
      <phone>410-614-8297</phone>
      <email>ndesai13@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Niraj Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert A Montgomery, MD</last_name>
      <phone>646-501-2418</phone>
      <email>robert.montgomery@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Robert A Montgomery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Legendre, MD</last_name>
      <phone>+33 1 44 49 53 55</phone>
      <email>Christophe.legendre@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Legendre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torbjörn Lundgren, MD</last_name>
      <phone>+46 73 6994946</phone>
      <email>torbjorn.lundgren@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Torbjörn Lundgren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bengt von Zur-Mühlen, MD</last_name>
      <phone>+46 18-611 00 00</phone>
      <email>bengt.muhlen@medsci.uu.se</email>
    </contact>
    <investigator>
      <last_name>Bengt von Zur-Mühlen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

